Treatment of fragile X syndrome with cannabidiol
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
1. A method of reducing social avoidance behavior associated with a human suffering from Fragile X Syndrome comprising administering a therapeutically effective amount of synthetic cannabidiol to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.
2. The method of claim 1 , wherein the cannabidiol is (-)-cannabidiol.
3. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is 250 mg total daily.
4. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is 500 mg total daily.
5. The method of claim 1 , wherein the cannabidiol is formulated as a permeation-enhanced gel.
6. The method of claim 1 , wherein the cannabidiol is administered in a single-daily dose.
7. The method of claim 1 , wherein the cannabidiol is administered in two daily doses.
8. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is between about 50 mg to 500 mg total daily.